Australia markets close in 5 hours 51 minutes

Cellectis S.A. (CMVLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
13.660.00 (0.00%)
At close: 12:36PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.66
Open13.66
Bid0.00 x 0
Ask0.00 x 0
Day's range13.66 - 13.66
52-week range12.99 - 33.48
Volume200
Avg. volume20
Market cap621.001M
Beta (5Y monthly)2.21
PE ratio (TTM)N/A
EPS (TTM)-2.78
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Monthly information on share capital and company voting rights

    (Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights08/31/202145,465,31051,067,217 About CellectisCellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-

  • GlobeNewswire

    Cellectis Announces Participation in Five Investor Conferences

    NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic diseases, today announced that management plans to participate in five virtual investor conferences. 11th Annual Biotech Symposium (Goldman Sachs) Date: Tuesday, September 7, 2021Time: 8AM-6PM (GMT) Citi’s 16th

  • Motley Fool

    Cellectis SA (CLLS) Q2 2021 Earnings Call Transcript

    At this time, I'll now turn the conference over to Eric Dutang, Chief Financial Officer. Thank you, and welcome everyone to Cellectis' second quarter 2021 corporate update and financial results conference call. Joining me on the call today with prepared remarks is Dr. Andre Choulika, our Chief Executive Officer; Dr. Carrie Brownstein, our Chief Medical Officer; and Steve Doares, our Senior Vice President of U.S. Manufacturing will be joining for the Q&A.